Informed Consent for Antenatal Serum Screening for Down Syndrome  by Hwa, Hsiao-Lin et al.
Taiwan J Obstet Gynecol • March 2010 • Vol 49 • No 1
■ ORIGINAL ARTICLE ■
50
Introduction
Respect for autonomy and improving patients’ under-
standing of the issues of early detection is one of the
most important principles in medical ethics [1]. Patients
should be provided with explicit information before un-
dergoing screening tests, because patients intending to
undergo screening must first weigh the potential benefits
of screening against the potential risks. It is crucial that
they are enabled to make informed decisions based on
relevant knowledge, consistent with their own values
and their behavioral inclinations [2,3]. This is particu-
larly true in the situation of antenatal screening for fetal
chromosomal abnormalities given the possible conse-
quences of invasive diagnostic procedures and possible
termination of affected pregnancies.
The focus of the present study was on patient under-
standing of prenatal serum screening for Down syn-
drome upon informed consent. Currently, the second-
trimester antenatal serum screening is the most widely
used screening strategy, with a sensitivity of 50–76%, at a
5% false-positive rate [4–6]. Women with a risk of 1/270
or greater are designated screen-positive and will be sug-
gested to undertake amniocentesis for prenatal diagno-
sis in Taiwan. Antenatal serum screening test fees for
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Down syndrome and amniocentesis are paid by the
pregnant women themselves in this country. This screen-
ing test has been taken as a part of regular prenatal
routine tests in many obstetric clinical settings and has
achieved a high participation rate in Taiwan. However,
the high participation rate may not reflect a high level of
informed choice [7,8]. The level of awareness of about
serum screening and thus a woman’s ability to make an
informed choice about whether to participate has not
been studied.
The anxiety and/or depression levels of patients
before counseling, prenatal screening or prenatal diag-
nostic testing has been quantified [9–11]. Genetic coun-
seling significantly reduced screen-positive women’s
anxiety level regardless of whether an amniocentesis was
performed [10]. However, the effect of counseling before
antenatal serum screening on anxiety or depression levels
has barely been evaluated.
In this study, we aimed to assess the patients’ 
perceived level of understanding of antenatal serum
screening for Down syndrome to evaluate the status of
informed consent in Taiwan. We also measured anxiety
and depression levels before the screening test.
Materials and Methods
This study was conducted in a medical center in Taipei
offering maternal serum screening with the triple test
(based on maternal age and serum concentrations of α-
fetoprotein, human chorionic gonadotropin, and uncon-
jugated estriol) between 2002 and 2003. This test was
suggested and explained to pregnant women by obste-
tricians at routine prenatal care during the 15th to 21st
gestational week. A leaflet about the test was given dur-
ing the visit. Women who desired the test would undergo
an ultrasound scan and blood withdrawal for the test on
the same day, after they had paid for the test and signed
an informed consent form.
This was a prospective, descriptive study of the
women after they had been offered the antenatal serum
screening for Down syndrome and had signed the in-
formed consent for the screening test, but before they
had undergone blood withdrawal. Women eligible for
the study comprised those who intended to undergo the
prenatal serum test, were at 15–21 weeks’ gestation, and
had booked for the continuing prenatal care at this med-
ical center. We excluded women with a previous history
of children with chromosomal abnormalities or con-
genital malformation, and women who were not suffi-
ciently fluent in Mandarin or Taiwanese.
Women who gave written informed consent to par-
ticipate in this study were randomly assigned into either
the experimental group or the control group. Participants
were asked to complete a questionnaire administered
by a trained researcher. Questionnaires were completed
before and after genetic counseling provided by the re-
searcher in the control group and experimental group,
respectively. The interview lasted 30 minutes on average,
and the questionnaires contained questions pertaining
to the women’s perceived level of understanding of ante-
natal serum screening, their level of knowledge about
the serum screening test, and anxiety as well as depres-
sion levels, in addition to questions concerning sociode-
mographic characteristics and obstetric history. Most
questions were of the yes/no or multiple choice variety.
For some items, women responded on a four-point scale.
The genetic counseling offered by the researcher in-
cluded information on: (1) the background age-related
risks of having a fetus affected by Down syndrome, (2)
the nature of Down syndrome and its related medical
and social issues, (3) serum makers and the procedure of
serum screening, (4) the meaning of the risk estimated by
screening, (5) the cutoff risk of 1/270 at mid-trimester,
(6) the percentage of false-positives, (7) the follow-up
action for screen-positive (usually amniocentesis) and
screen-negative cases (no action), (8) the amniocentesis-
related hazards, (9) the limitations of serum screening
tests in detecting affected fetuses, and (10) a quoted
sensitivity of 60% for mid-trimester screening tests [12].
The primary endpoints were the perceived level of
understanding of relevant information about antenatal
serum screening, knowledge about Down syndrome and
serum screening, the source of their knowledge, and at-
titudes toward this screening test, including the rea-
sons for undergoing the test. To assess knowledge about
serum tests and the autonomy of the decision to take
the test, the questionnaire used multiple choice ques-
tions modified from previous reports [13–16].
Secondary endpoints were the anxiety and depres-
sion levels of these pregnant women. Anxiety levels were
evaluated by the short form of the state scale of the
Spielberger State-Trait Anxiety Inventory (STAI), which
consisted of a 20-item state anxiety scale designed for
assessing the transient situation-related stress level [17].
Patients were asked to rate each item on a scale of 1 to 4.
The scores obtained on the STAI can range from 20 to
80. A higher score means a greater level of anxiety in
the patient. The STAI has been translated into Chinese
and has been validated [18,19]. Scores were prorated
to be equivalent to those obtained using the full form of
the scale. The mean norm of anxiety levels in the general
population samples of women is 36.85 [20]. To assess
generalized depression, we used the Taiwanese Depres-
sion Questionnaire (TDQ), as it is short but suffici-
ently sensitive for the detection of clinically worthwhile 
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differences [21,22]. The TDQ is an 18-item, self-report
scale assessing common symptoms of depression.
Each item is assessed on a four-point scale (from 0 to 3),
and the total scores may range from 0 to 54. It has a
sensitivity of 0.89 and a specificity of 0.92 at a cutoff
score of 19 [21,22]. The area under the receiver oper-
ating characteristics curves of the TDQ was 0.92, and
the reliability of internal consistency (Cronbach α coef-
ficient) was 0.90, which was quite satisfactory.
Statistical analyses
Categorical data were analyzed using the χ2 test. Con-
tinuous data were analyzed using the Student’s t test
for normally distributed variables and the Mann-
Whitney U test when distributions were skewed. All
statistical analyses were conducted using SPSS 10.0
computer software (Statistical Package for Social
Sciences, Inc., Chicago, IL, USA). A two-tailed p < 0.05
was considered statistically significant.
Results
Among the 220 approached women, 193 women
(87.7%) agreed to participate in this study and com-
pleted the questionnaires. Women allocated to the
experimental group (96 women) and those in the con-
trol group (97 women) were similar in their sociode-
mographic characteristics and obstetric background,
with no statistically significant differences between the
two groups (Table 1).
Table 2 presents the perceived level of understanding
of the nature of Down syndrome and the level of under-
standing of informed consent about prenatal serum
screening in both groups. Participants in the experi-
mental group had statistically significantly higher per-
ceived levels of understanding of the disease nature of
Down syndrome and aspects of the antenatal screening
test than the participants in the control group (Table 2).
The overall level of knowledge about Down syndrome
Table 1. Sociodemographic and obstetric characteristics among patients in the experimental and control groups*
Items Experimental (n = 96) Control (n = 97) p
Age, mean ± SD (yr) 30.8 ± 3.1 31.1 ± 3.5 0.63
Gestational week, mean ± SD (wk) 16.4 ± 1.4 16.2 ± 1.1 0.28
Education
Senior high school or below 27 (28.1) 22 (22.7) 0.41
College or above 69 (71.9) 75 (77.3)
Marital status
Married 93 (96.9) 95 (97.9) 0.68
Unmarried 3 (3.1) 2 (2.1)
Parity
Nullipara 62 (64.6) 64 (66.0) 0.88
Multipara 34 (35.4) 33 (34.0)
Religion
Christian 13 (13.5) 10 (10.3) 0.22
Buddhism 46 (47.9) 53 (54.6)
Taoism 14 (14.6) 16 (16.5)
Others 23 (24.0) 15 (15.5)
Previous experience of serum screening
No 73 (76.0) 73 (75.3) > 0.99
Yes 23 (24.0) 24 (24.7)
Previous experience of amniocentesis
No 93 (96.9) 95 (97.9) 0.68
Yes 3 (3.1) 2 (2.1)
Monthly family income
≤ NT$49,999 16 (16.7) 17 (17.5) 0.76
NT$50,000–99,999 57 (59.4) 61 (62.9)
≥ NT$100,000 23 (24.0) 19 (19.6)
*Data are presented as n (%).
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Table 2. Perceived level of understanding about Down syndrome and antenatal serum screening among patients in the
experimental and control groups*
Items Experimental (n = 96) Control (n = 97) p
Understanding of the nature of Down syndrome
Quite well 49 (51.0) 19 (19.6) < 0.001
Somewhat 44 (45.8) 62 (63.9)
Barely or not at all 3 (3.1) 16 (16.5)
Understanding of the reason for serum screening
Quite well 68 (70.8) 45 (46.4) 0.001
Somewhat 27 (28.1) 43 (44.3)
Barely or not at all 1 (1.0) 9 (9.3)
Understanding of the method of serum screening
Quite well 50 (52.1) 34 (35.1) < 0.001
Somewhat 45 (46.9) 39 (40.2)
Barely or not at all 1 (1.0) 24 (24.7)
Understanding of biomarkers being used for screening
Quite well 43 (44.8) 20 (20.6) < 0.001
Somewhat 50 (52.1) 39 (40.2)
Barely or not at all 3 (3.1) 38 (39.2)
Understanding of the meaning of the results of 
serum screening
Quite well 48 (50.0) 15 (15.5) < 0.001
Somewhat 44 (45.8) 22 (22.7)
Barely or not at all 4 (4.2) 60 (61.9)
Understanding of the content of informed consent
Quite well 65 (67.7) 38 (39.2) < 0.001
Somewhat 31 (32.3) 44 (45.4)
Barely or not at all 0 (0) 15 (15.5)
Enough time to understand the informed consent 
before making a decision
Quite enough 52 (54.2) 34 (35.1) 0.002
Somewhat 41 (42.7) 48 (49.5)
Barely or not at all 3 (3.1) 15 (15.5)
*Data are presented as n (%).
and the screening test of respondents in the experimental
group were higher than those of participants in the con-
trol group (Table 3). Fifty-one percent of respondents in
the experimental group made the decision themselves
to undergo serum screening, whereas only 36.1% of
women in the control group made the decision them-
selves (p = 0.03). The majority of participants (74.0% of
women in the experimental group and 60.8% of women
in the control group) would undergo amniocentesis
when they were informed of a screen-positive result;
there was no significant difference between these two
groups. About half the respondents in the experimen-
tal group (50.0%) and in the control group (46.4%)
stated that the serum screening would be taken as an
index and would help them to make a well-informed
decision about whether to have amniocentesis or not.
The STAI scores did not differ between the experi-
mental group and the control group (44.3 ± 6.1 vs.
43.0 ± 5.7; p = 0.14). No statistically significant differ-
ences between the experimental group and the 
control group were observed in the scores of the TDQ
for depressive symptoms (12.2 ± 8.8 vs. 12.6 ± 7.5;
p = 0.75).
Discussion
Clinical guidelines for physicians on obtaining informed
consent indicate that patients have the right to be in-
formed about their condition and the treatment options
available to them [1]. In addition to a professional
recommendation, health care providers should give a
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Table 3. Level of knowledge about Down syndrome and antenatal serum screening among patients in the experimental 
group and control group*
Items Experimental (n = 96) Control (n = 97) p
Knowledge level about the nature of Down syndrome
Correct 47 (49.0) 34 (35.1) 0.06
Incorrect 49 (51.0) 63 (64.9)
Knowledge about the methods for fetal Down 
syndrome detection
Correct 23 (24.0) 26 (26.8) 0.54
Incorrect 73 (76.0) 70 (72.2)
Knowledge about the time period for serum screening
Correct 91 (94.8) 92 (94.8) 0.99
Incorrect 5 (5.2) 5 (5.2)
Knowledge about the detection rate of mid-trimester 
serum screening 
Correct 84 (87.5) 77 (79.4) 0.14
Incorrect 11 (11.5) 20 (20.6)
Knowledge about reasons for the incorrect estimation 
of risk 
Correct 50 (52.1) 43 (44.3) 0.24
Incorrect 46 (47.9) 52 (53.6)
Knowledge about the meaning of screening-positive
Correct 95 (99.0) 88 (90.7) 0.04
Incorrect 1 (1.0) 8 (8.2)
Knowledge about the meaning of screening-negative
Correct 77 (80.2) 75 (77.3) 0.80
Incorrect 18 (18.8) 20 (20.6)
Total items
Correct 467 (69.7) 435 (64.6) 0.048
Incorrect 203 (30.3) 238 (35.4)
*Data are presented as n (%).
balanced view of the options to patients, in words they
can understand, and give them enough time to consider
the options. Pregnant women offered screening tests
have the privilege of making judgments on their own
behalf and evaluating the risks and benefits of the
screening program [23,24]. Therefore, the degree to
which women are adequately informed about antenatal
serum screening should be of interest. Comprehensive
counseling on maternal serum screening should be pro-
vided by health service professionals. This information
can help patients improve their knowledge of the nature
of the disease and test, encourage realistic expecta-
tions of the possible benefits and hazards of the options,
increase patients’ involvement in decision making, and
reduce those patients’ decisional conflicts that grow
out of a feeling of being incompletely informed [2,3,25].
In this study, comprehensive genetic counseling about
serum screening for Down syndrome helped pregnant
women to make their own decision whether to undergo
the screening test. The results of this study indicate that
women’s perceived level of understanding of the ante-
natal serum screening test and level of knowledge
about this test are significantly higher when genetic
counseling is individually provided by a trained coun-
selor separately than when a short description accom-
panied by a leaflet was offered by the obstetrician at a
routine visit. The difference cannot be explained by age,
religion, parity, previous experience with an antenatal
serum test, or the socioeconomic status of the study
population. In spite of the high uptake rates of serum
screening in this medical center, the perceived level of
understanding of this test was relatively low in the con-
trol group. A short explanation by obstetricians with a
leaflet does not lead to the patients’ full understanding
of the screening test, even though patients did sign their
informed consent forms for the test. The success of a
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screening program should be assessed on the basis of
the proportion of patients who can reach a truly in-
formed decision, rather than on the attendance rates
[26,27].
With the use of the STAI and TDQ, we quantified the
levels of anxiety and depression of the women before
antenatal serum screening and the effect that compre-
hensive genetic counseling can have on these levels. The
state anxiety scores and depression levels did not differ
between the two groups. Our study failed to demon-
strate any effect of genetic counseling on anxiety or
depression in women participating in antenatal serum
screening. Furthermore, the study indicates that anxiety
and depression were neither alleviated nor exacerbated
by counseling before the test results were revealed.
These results differed from previous reports of screen-
positive women where anxiety level was reduced after
genetic counseling. In these studies, anxiety level was
elevated in screen-positive women, only to be allevi-
ated once counseling revealed the possibility of a false-
positive result [10,28].
In conclusion, women are not given enough infor-
mation to allow them to make an informed decision
about receiving antenatal serum screening for Down
syndrome when the test is offered during the routine
clinical visit with a short description accompanied by a
leaflet. A trained counselor providing pregnant women
with counseling about this screening test significantly
improves the patients’ knowledge about the test, and
obviously encourages the patients’ informed choice.
Health service providers should do their best to meet
the ethical requirements of informed consent for ante-
natal serum screening.
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